RE:RE:RE:RE:RE:RE:RE:News out N newsalerts@resverlogix.mediaroom.com
Probably correct. I'm hoping that since they had the parameters down for a European trial last October - as well as the Diabetes data - that they have been working with the FDA/EMA on the latest design and can hit the ground running sooner than later. Very wishfull thinking based on their history - maybe early 2018??? I guess we should be happy that they seem to be moving forward cautiously and trying to figure out how to get the biggest bang out of the study, giving the utmost consideration to time and costs. I like phase 3 better than rolling phase 2/3.